Galectin Therapeutics (GALT) Rating Lowered to Hold at ValuEngine

ValuEngine lowered shares of Galectin Therapeutics (NASDAQ:GALT) from a buy rating to a hold rating in a report published on Saturday, April 13th, ValuEngine reports.

Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Galectin Therapeutics from a strong-buy rating to a hold rating in a research note on Wednesday, February 20th. B. Riley began coverage on shares of Galectin Therapeutics in a research note on Thursday, March 7th. They issued a buy rating and a $11.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $9.42.

GALT traded up $0.15 during trading on Friday, hitting $4.60. The stock had a trading volume of 350,800 shares, compared to its average volume of 459,452. The stock has a market capitalization of $209.53 million, a P/E ratio of -12.11 and a beta of 3.54. Galectin Therapeutics has a twelve month low of $3.10 and a twelve month high of $9.49.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.08) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.08). On average, sell-side analysts anticipate that Galectin Therapeutics will post -0.58 EPS for the current fiscal year.

In other news, Director Marc Rubin sold 51,185 shares of the stock in a transaction dated Friday, February 22nd. The shares were sold at an average price of $6.02, for a total transaction of $308,133.70. Following the transaction, the director now directly owns 13,581 shares in the company, valued at approximately $81,757.62. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard E. Uihlein acquired 20,700 shares of the business’s stock in a transaction dated Tuesday, April 9th. The shares were bought at an average price of $4.82 per share, for a total transaction of $99,774.00. Following the completion of the acquisition, the director now owns 2,628,489 shares in the company, valued at $12,669,316.98. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 22,700 shares of company stock worth $108,574. 45.20% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in GALT. Vanguard Group Inc raised its holdings in Galectin Therapeutics by 18.7% in the third quarter. Vanguard Group Inc now owns 1,432,576 shares of the company’s stock valued at $8,609,000 after buying an additional 225,822 shares during the period. Vanguard Group Inc. grew its position in Galectin Therapeutics by 18.7% in the third quarter. Vanguard Group Inc. now owns 1,432,576 shares of the company’s stock valued at $8,609,000 after acquiring an additional 225,822 shares in the last quarter. Barclays PLC grew its position in Galectin Therapeutics by 2,711.6% in the fourth quarter. Barclays PLC now owns 174,603 shares of the company’s stock valued at $599,000 after acquiring an additional 168,393 shares in the last quarter. Advisor Group Inc. grew its position in Galectin Therapeutics by 12.8% in the fourth quarter. Advisor Group Inc. now owns 674,291 shares of the company’s stock valued at $2,313,000 after acquiring an additional 76,489 shares in the last quarter. Finally, Tibra Equities Europe Ltd acquired a new stake in Galectin Therapeutics in the first quarter valued at approximately $371,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Read More: Price to Earnings Ratio (PE) Basics

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.